QT
ASND icon

Quantamental Technologies’s Ascendis Pharma A/S ASND Stock Holding History

Quantamental Technologies’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-400
Closed -$25K – 1465
2018
Q4 		$25K Buy
+400
New +$25.1K 0.01% 971

Other funds holding ASND

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quantamental Technologies's ASND Position: Q1 2019 in Review

Quantamental Technologies sold out of Ascendis Pharma A/S (ASND) in Q1 2019, closing a stake of 400 shares — an estimated $25K sold.

Quantamental Technologies first reported a position in ASND in Q4 2018 and held it in 1 quarter. The position peaked at $25K in Q4 2018. 138 funds tracked by Wall St. Rank hold ASND as of Q1 2019.

  • Quantamental Technologies reported no remaining Ascendis Pharma A/S position as of Q1 2019 after selling out during the quarter.
  • Quantamental Technologies sold 400 Ascendis Pharma A/S shares in Q1 2019, an estimated $25K.
  • Quantamental Technologies first reported a position in Ascendis Pharma A/S in Q4 2018 and held it in 1 quarter.
  • Quantamental Technologies's Ascendis Pharma A/S position peaked at $25K in Q4 2018.
  • 138 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2019.

Based on Quantamental Technologies's 13F filing for Q1 2019, filed 29 Apr 2019.